Adlai Nortye Biopharma Co., Ltd.

New phase 1 trial NCT07686445 posted by Adlai Nortye Biopharma Co., Ltd.: "A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression". New trial on a phase 1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 56 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 1 trial NCT07252479 posted by Adlai Nortye Biopharma Co., Ltd.: "Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 92 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.